Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

scPharmaceuticals Inc. - Common Stock (NQ:SCPH)

2.600 -0.180 (-6.47%)
Streaming Delayed Price Updated: 10:50 AM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 276,840
Open 2.760
Bid (Size) 2.590 (3)
Ask (Size) 2.600 (6)
Prev. Close 2.780
Today's Range 2.500 - 2.765
52wk Range 2.720 - 5.650
Shares Outstanding 35,769,073
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations For scPharmaceuticals's Future
Via Benzinga
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From scPharmaceuticals Inc.
Via GlobeNewswire

Performance

YTD
-27.2%
-27.2%
1 Month
-20.7%
-20.7%
3 Month
-25.7%
-25.7%
6 Month
-43.0%
-43.0%
1 Year
-46.4%
-46.4%

More News

Read More
Earnings Scheduled For March 19, 2025
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
scPharmaceuticals's Earnings Outlook
Via Benzinga
Recap: scPharmaceuticals Q4 Earnings
Via Benzinga
A Preview Of scPharmaceuticals's Earnings
Via Benzinga
Recap: scPharmaceuticals Q3 Earnings
Via Benzinga
Wondering what's happening in today's after-hours session?
Via Chartmill
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
From scPharmaceuticals Inc.
Via GlobeNewswire
SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization
Via Benzinga
Exposures Product Safety
Earnings Preview: scPharmaceuticals
Via Benzinga
Earnings Outlook For scPharmaceuticals
Via Benzinga
The Latest Analyst Ratings for scPharmaceuticals
Via Benzinga
7 Short-Squeeze Stocks That Could Beat Down the Bears
Via InvestorPlace
SCPH Stock Earnings: scPharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Earnings Outlook For scPharmaceuticals
Via Benzinga
Earnings Scheduled For March 13, 2024
Via Benzinga
Dow Up 150 Points; Gold Jumps Over 2%
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
Via Benzinga
Earnings Scheduled For August 10, 2023
Via Benzinga
Analyst Ratings for scPharmaceuticals
Via Benzinga

Frequently Asked Questions

Is scPharmaceuticals Inc. - Common Stock publicly traded?
Yes, scPharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does scPharmaceuticals Inc. - Common Stock trade on?
scPharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for scPharmaceuticals Inc. - Common Stock?
The ticker symbol for scPharmaceuticals Inc. - Common Stock is SCPH on the Nasdaq Stock Market
What is the current price of scPharmaceuticals Inc. - Common Stock?
The current price of scPharmaceuticals Inc. - Common Stock is 2.600
When was scPharmaceuticals Inc. - Common Stock last traded?
The last trade of scPharmaceuticals Inc. - Common Stock was at 03/31/25 10:50 AM ET
What is the market capitalization of scPharmaceuticals Inc. - Common Stock?
The market capitalization of scPharmaceuticals Inc. - Common Stock is 93.00M
How many shares of scPharmaceuticals Inc. - Common Stock are outstanding?
scPharmaceuticals Inc. - Common Stock has 93M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.